| Contact Us | +41 21 691 43 75 | info@genepredictis.com | EPFL Innovation Park (bâtiment B) | 1015 Lausanne | Switzerland |
| Contact Us |
| +41 21 691 43 75 |
| info@genepredictis.com |
| EPFL Innovation Park (bâtiment B) |
| 1015 Lausanne |
| Switzerland |
Gene Predictis provides analyses for COVID-19
Gene Predictis SA helps to fight the current pandemic Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Our laboratory offers a complete range of tests related to COVID-19:
- The diagnostic test – a PCR-based test that detects specifically the viral RNA, it is performed when the symptoms of the disease are present.
- Antibody tests – ELISA test that determines if a person was in contact with SARS-CoV-2 virus and has developed antibodies against the virus.
For more information COVID-19
Gene Predictis wins two International Life Sciences Awards
Gene Predictis SA, a Swiss company at the leading edge of precision medicine, is a winner of the two prestigious 2019 International Life Sciences Awards, awarded by Global Health & Pharma:
1) Most Pioneering Precision Medicine Company – Europe
2) Best Pharmacogenetics Product – Pill Protect
The company was selected by an international jury of Global Health & Pharma, based on its technology and business opportunity, as one of the most promising companies in the Life Sciences space.
https://www.ghp-news.com/issues/intl-life-sciences-awards-2019/11/#zoom=z
Gene Predictis is happy to announce its collaboration with the world leader in longevity and well-being Clinique La Prairie.
Clarens-Montreux (Switzerland), December 17, 2018 – Clinique La Prairie (CLP), an international leader in longevity and wellness, is pleased to announce its partnership with the Swiss company Gene Predictis®, a pioneer and recognized expert in precision medicine
Discover the latest AGEFI article on Gene Predictis
The well-known AGEFI newspaper recently published an article on Gene Predictis. It describes the importance of genetic tests such as CYPASS to avoid drugs adverse effects and, it also focuses on the society new goals to conquer new international markets. Find the original article below:
Nutripass, first nutrigenetic test reimbursed in Switzerland
Gene Predictis Nutripass genetic test is now reimbursed by Helsana Health Insurance and its supplementary insurance PRIMEO. This test is a unique tool that assesses each person’s genetic ability to metabolize frequently used foods and optimize their intake of important nutrients. It also assesses the risk of developing food intolerances and diet-related diseases. It thus makes it possible to personalize nutritional advice and nutrition in accordance with genes.
As part of the review of the law on human genetic analysis, the Swiss national television channel RTSinfo interviewed Gene Predictis SA
As part of the Swiss parliament’s review of the law on human medical genetics, the Swiss national television channel RTSinfo met with the CEO of Gene Predictis SA, Ms Goranka Tanackovic, to interview her on the role of genetic testing and “lifestyle” tests. Find the link to the video below:
In the same vein, Gene Predictis SA’s chief scientist Joëlle Michaud was also interviewed by the Swiss newspaper Le Nouvelliste. She pointed out the importance of working with physicians. Find the article below:
Article from Le Nouvelliste: “Vers des tests génétiques «lifestyle»”_mars 2018
Scientific publication confirming the efficacy of Pill Protect®, an innovative genetic test to assess the risk of thrombosis in women using contraceptive pill
Gene Predictis®, in collaboration with the group of Prof. Zoltàn Kutalik at CHUV (University Hospital of Canton Vaud) and the SIB Swiss Institute of Bioinformatics, published a study concerning Pill Protect® test, an innovative medical test that uses genetic data to identify women at risk of developing thrombosis when using contraceptive pills. This study identified two new genetic markers associated with the development of thrombosis as well as a combination of specific clinical and genetic factors to measure the risk of thrombosis in women using combined oral contraceptives. Pill Protect® is already available in Switzerland and reimbusrsed, it helps to identify women at risk more effectively and precisely than ever before.
Two innovative genetic tests Pill Protect® and Cypass® reimbursed by supplementary insurance
As of November 1st, 2016, Gene Predictis’ genetic tests Pill Protect® and Cypass® are reimbursed by supplementary healthcare cover PRIMEO from Helsana, the leading insurance group in Switzerland. These tests allow to evaluate, for every individual, the risk of adverse drug events by integrating both patient’s genetics and clinical data. This represents a significant step forward towards personalization of care for patients on one hand and preventive medicine on the other.